Recursion Pharmaceuticals Inc
RXRX5.490USD
-0.030-0.54%
收盘 10/03, 16:00（美东）报价延迟15分钟
2.37B总市值
亏损市盈率 TTM
关于 Recursion Pharmaceuticals Inc 公司
Recursion Pharmaceuticals, Inc. 是一家临床阶段的 TechBio 公司，致力于解码生物学，实现药物研发的工业化。其 Recursion 操作系统 (OS) 是一个跨多种技术构建的平台，使公司能够映射和导航 Recursion 数据宇宙中的数万亿生物和化学关系。该公司将物理和数字组件集成为原子和比特的迭代循环，将湿实验室生物学和化学数据组织成良性循环，并使用计算工具将计算机假设快速转化为经过验证的见解和新颖的化学反应。其临床项目包括 REC-994、REC-2282、REC-4881 和 REC-3964。REC-994 是一种口服生物可利用的超氧化物清除剂小分子，正在开发用于治疗有症状的脑海绵状畸形 (CCM)。 REC-2282 用于潜在治疗 2 型神经纤维瘤病。REC-3964 用于预防复发性艰难梭菌感染。
Recursion Pharmaceuticals Inc简介
公司代码RXRX
公司名称Recursion Pharmaceuticals Inc
上市日期Apr 16, 2021
CEODr. Christopher Gibson, Ph.D.
员工数量840
证券类型Ordinary Share
年结日Apr 16
公司地址41S Rio Grande Street
城市SALT LAKE CITY
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编84101
电话13852690203
网址https://www.recursion.com/
公司代码RXRX
上市日期Apr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Recursion Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
147.47K
-4.57%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
138.76K
+2.17%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
15.52K
--
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
147.47K
-4.57%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
138.76K
+2.17%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
15.52K
--
收入明细
单位: USD更新时间: 10月2日 周四
单位: USD更新时间: 10月2日 周四
FY2025Q2
FY2025Q1
暂无数据
地区USD
名称
营收
占比
United States
11.79M
61.73%
United Kingdom
7.31M
38.27%
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
其他
69.16%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
其他
69.16%
股东类型
持股股东
占比
Investment Advisor
43.28%
Investment Advisor/Hedge Fund
10.46%
Venture Capital
7.26%
Sovereign Wealth Fund
3.78%
Individual Investor
2.93%
Research Firm
1.97%
Corporation
1.80%
Hedge Fund
1.52%
Bank and Trust
0.83%
其他
26.18%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
654
296.43M
69.37%
-20.49M
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
36.00M
8.43%
+3.77M
+11.70%
Jun 30, 2025
ARK Investment Management LLC
32.99M
7.72%
-1.83M
-5.25%
Jun 30, 2025
Baillie Gifford & Co.
24.17M
5.66%
-219.20K
-0.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
23.93M
5.6%
+3.86M
+19.23%
Jun 30, 2025
SB Global Advisers Ltd
14.67M
3.43%
--
--
Jun 30, 2025
Kinnevik AB
13.43M
3.14%
--
--
Jun 30, 2025
Mubadala Investment Company PJSC
12.99M
3.04%
--
--
Jun 30, 2025
State Street Global Advisors (US)
11.18M
2.62%
-1.91M
-14.56%
Jun 30, 2025
Novo Holdings A/S
9.67M
2.26%
--
--
Jun 30, 2025
MIC Capital Management UK LLP
9.64M
2.26%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
ARK Genomic Revolution ETF
5.18%
First Trust Nasdaq AI and Robotics ETF
1.71%
AXS Green Alpha ETF
1.19%
ARK Innovation ETF
1.18%
Franklin Genomic Advancements ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.71%
WisdomTree BioRevolution Fund
0.7%
SPDR S&P Biotech ETF
0.41%
WisdomTree Artificial Intelligence and Innov Fund
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
查看更多
ARK Genomic Revolution ETF
占比5.18%
First Trust Nasdaq AI and Robotics ETF
占比1.71%
AXS Green Alpha ETF
占比1.19%
ARK Innovation ETF
占比1.18%
Franklin Genomic Advancements ETF
占比0.91%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.71%
WisdomTree BioRevolution Fund
占比0.7%
SPDR S&P Biotech ETF
占比0.41%
WisdomTree Artificial Intelligence and Innov Fund
占比0.32%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.25%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
